Benjamin Belot combines a biotechnology engineering degree from École Supérieure de Biotechnologie de Strasbourg with an MBA from INSEAD, plus hands-on experience in high-throughput screening and data-driven R&D in pharma before becoming an investor. He has positioned himself as a specialist at the intersection of AI and health/biotech, authoring Kurma's public framework on digital therapeutics and regularly speaking at global healthtech conferences about AI's role in drug discovery and healthcare transformation.
About their Fund
Kurma Partners operates two specialized healthcare franchises under one roof—Kurma Biofund for therapeutics and biotech company creation from academic labs, and Kurma Diagnostics for diagnostics and digital health—while offering a full innovation-to-growth continuum through its dedicated Growth Opportunities Fund that continues financing promising portfolio companies into scale-up rounds. The firm has built a systematic company-creation engine with major European research institutes like Institut Pasteur and VIB, spinning out academic research into venture-backed companies and providing portfolio companies with operational support through strategic partnerships like its alliance with Samsung Biologics for development and manufacturing capabilities.
















.jpeg)







.jpeg)











































































.png)
























































































































.jpeg)









.jpeg)




















































































